Rita Di Gianfilippo

Suggest Changes
Learn More
Forty-six patients with chronic myeloid leukemia receiving imatinib mesylate (39 in chronic phase, one in accelerated phase, and six in blastic crisis), were studied for a 20-62 month follow-up(More)
  • 1